TNF and colitis: Refractory skin irAEs can be managed with secukinumab, an anti-IL17 antibody, steroid-refractory colitis with infliximab, a monoclonal antibody against the tumor necrosis factor (TNF), some other therapies like tocilizumab and rapamycin for GI or hematological irAEs and allograft tolerance for solid organ transplantation respectively are still experimental and are associated with various other adverse effects [47].